How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
In Vitro Gene Therapy Market
- By Vector Type: Adenoviral Vectors, Lentiviral Vectors, Adeno-Associated Viral (AAV) Vectors, Retroviral Vectors, Non-viral Vectors
- By Therapeutic Application: Oncology, Cardiovascular Diseases, Neurological Disorders, Genetic Disorders, Infectious Diseases
- By Gene Modification Technique: Gene Addition, Gene Editing (CRISPR/Cas9, TALENs, ZFNs), Gene Silencing (RNAi, siRNA), Gene Replacement
- By End User: Research Institutes, Pharmaceutical and Biotechnology Companies, Hospitals and Clinics, Contract Research Organizations (CROs)
- By Delivery Method: Ex Vivo Gene Therapy, In Vivo Gene Therapy
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Adenoviral Vectors leads By Vector Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 17 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 298 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.177 →
- 12 Company Profiles 17 players: SWOT & benchmarking p.185 →
Full report · locked preview
Everything inside the In Vitro Gene Therapy Market report
A complete, evidence-based study - 12 chapters and 125 sections covering market size, segmentation across 5 axes, regional analysis and 17 company profiles, forecast to 2033.
Segmentation covered
Vector Type 5
Therapeutic Application 5
Gene Modification Technique 4
End User 4
Delivery Method 2
Companies profiled
Novartis AG
Bluebird Bio Inc.
Sangamo Therapeutics Inc.
uniQure N.V.
Spark Therapeutics
Inc. (a Roche company)
REGENXBIO Inc.
Audentes Therapeutics
Inc. (a subsidiary of Astellas Pharma)
Homology Medicines Inc.
MeiraGTx Holdings plc
Bristol-Myers Squibb Company
+5 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
17 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Novartis AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Bluebird Bio Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Sangamo Therapeutics Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →uniQure N.V.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Spark Therapeutics
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Inc. (a Roche company)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →REGENXBIO Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Audentes Therapeutics
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Inc. (a subsidiary of Astellas Pharma)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Homology Medicines Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →MeiraGTx Holdings plc
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Bristol-Myers Squibb Company
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Pfizer Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.227 →Bayer AG
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Amgen Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Sanofi S.A.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Biogen Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.250 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$2,084M by 2033 · 10.5% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Adenoviral Vectors32.4
- Lentiviral Vectors14.3
- Adeno-Associated Viral (AAV) Vectors20.1
- Retroviral Vectors18.5
- Non-viral Vectors14.7
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$309.3M → $759.6M · 11.9%
Europe$215.6M → $464.0M · 10.1%
Asia Pacific$196.8M → $402.1M · 9.3%
Latin America$121.9M → $290.1M · 11.5%
Middle East and Africa$93.7M → $218.1M · 11.1%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →10.452026
10.462027
10.482028
10.492029
10.502030
10.512031
10.532032
10.542033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Novartis AG23.4
- Bluebird Bio Inc.14.1
- Sangamo Therapeutics Inc.4.4
- uniQure N.V.11.5
- Spark Therapeutics12.6
- Inc. (a Roche company)6.0
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Vector Type10.3%
Therapeutic Application27.4%
Gene Modification Technique25.2%
End User18.1%
Delivery Method19.0%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America35.6
- Europe21.7
- Asia Pacific18.8
- Latin America13.6
- Middle East and Africa10.2
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Novartis AG | 80 | 95 | 97 | 85 | 91 | 79 | 88 |
| Bluebird Bio Inc. | 79 | 85 | 69 | 79 | 70 | 76 | 76 |
| Sangamo Therapeutics Inc. | 84 | 64 | 78 | 84 | 64 | 66 | 73 |
| uniQure N.V. | 67 | 68 | 57 | 62 | 77 | 71 | 67 |
| Spark Therapeutics | 56 | 74 | 54 | 73 | 74 | 63 | 66 |
| Inc. (a Roche company) | 62 | 50 | 56 | 70 | 46 | 60 | 57 |
| REGENXBIO Inc. | 49 | 55 | 61 | 41 | 43 | 57 | 51 |
| Audentes Therapeutics | 46 | 52 | 44 | 46 | 60 | 36 | 47 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Novartis AG
- Bluebird Bio Inc.
- Sangamo Therapeutics Inc.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Novartis AG | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Bluebird Bio Inc. | ◐ | ◐ | ◐ | ✓ | ✓ | ◐ |
| Sangamo Therapeutics Inc. | ✓ | ◐ | ✓ | ◐ | ◐ | − |
| uniQure N.V. | ◐ | ✓ | − | ◐ | ◐ | ✓ |
| Spark Therapeutics | − | ✓ | − | ◐ | ◐ | − |
| Inc. (a Roche company) | − | − | ◐ | − | − | − |
| REGENXBIO Inc. | − | − | − | − | ◐ | ◐ |
| Audentes Therapeutics | − | ◐ | − | − | ◐ | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Novartis AG88
2Bluebird Bio Inc.76
3Sangamo Therapeutics Inc.73
4uniQure N.V.67
5Spark Therapeutics66
6Inc. (a Roche company)57
7REGENXBIO Inc.51
8Audentes Therapeutics47
Competitive tiers
§8.4 · p.172 →Leader1
Set the pace on share, breadth and innovation.
Novartis AG
Challenger3
Strong scale, closing on the leaders.
Bluebird Bio Inc.Sangamo Therapeutics Inc.uniQure N.V.
Contender2
Focused players with pockets of strength.
Spark TherapeuticsInc. (a Roche company)
Niche2
Specialists in a single segment or region.
REGENXBIO Inc.Audentes Therapeutics
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Vector Type in North America, then scale across In Vitro Gene Therapy Market — a $277M beachhead inside a $4.49B market.
Beachhead (SOM)$277Mobtainable near-term
Serviceable (SAM)$1.88Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion87 fit
Adenoviral Vectors
Best fit — highest urgency & budget in Vector Type.
Economic buyer75 fit
Lentiviral Vectors
Strong fit — clear ROI and a fast path to value.
End user64 fit
Adeno-Associated Viral (AAV) Vectors
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Vector Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Therapeutic Application & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Gene Modification Technique
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales45%
Partner / channel27%
Digital / self-serve21%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Vector Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win In Vitro Gene Therapy Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified40%
Sales qualified21%
Evaluation14%
Closed-won7%
$20.6KCAC
$110KLTV
5.3:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
In Vitro Gene Therapy Market is a durable-growth opportunity — $6.75B by 2033, compounding at 9.0%.
TAM · 2025$3.39Btoday
TAM · 2033$6.75Bforecast
CAGR9.0%2027–2033
Cumulative$44.2Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$6.75BTotal addressable market
SAM$2.76BServiceable available market
SOM$531MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →9.0% CAGR
Demand compounds through 2033, outpacing GDP across Vector Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Vector Type moving from early to mainstream — durable secular demand.
Consolidation upside
17+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$6.75BLarge & growingTAM by 2033 at 9.0% CAGR
$2.76BServiceable nowreachable with today’s model
$531MBeachhead winobtainable near-term share
17+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$5.27BBear5.8% CAGR
$6.75BBase9.0% CAGR
$8.65BBull11.9% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Therapeutic Application optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
In Vitro Gene Therapy Market — a $1.22B market by 2033. Plan: grow share from 9.6% to 16.7%.
Market size · 2033$1.22Btotal addressable
Market CAGR10.5%2027–2033
Target share16.7%from 9.6% today
Revenue ambition$204Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 9.6% | 16.7% | On track |
| Revenue | $114M | $204M | Ahead |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 36.6% | 38.9% | At risk |
| Customer retention | 87.9% | 96.0% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Vector Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Therapeutic Application capability
A defensible second engine — invest in Therapeutic Application to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Vector Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Therapeutic Application
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $22M capacity & capability investment
- Greenlight bolt-on M&A in Therapeutic Application
- Authorise North America expansion plan
- Fund R&D program for Vector Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossOn track
- Input-cost & supply riskAt risk
- Regulatory / policy changeBehind
- Execution & talentBehind
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the In Vitro Gene Therapy Market conversation — a $2.10B market you can size, segment and defend in minutes.
Market size · 2033$2.10Btotal opportunity
Growth11.7%CAGR to 2033
Addressable buyers980+accounts in scope
Typical ROI7.6×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Vector Type
Goal Grow share in Vector Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7.6×return on cost, year one
< 2 mopayback period
$79K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
17+players profiled in this market
Coverage includes
Novartis AGBluebird Bio Inc.Sangamo Therapeutics Inc.uniQure N.V.Spark TherapeuticsInc. (a Roche company)REGENXBIO Inc.Audentes Therapeutics+9 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your In Vitro Gene Therapy Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
In Vitro Gene Therapy Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →In Vitro Fertilization Test Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportIn-vitro Fertilization Microscope Market
Market size, share, segmentation and regional forecast.
$1.2B market · 2025 base year
View reportIn-vitro Fertilization (IVF) Microscopes Market
Market size, share, segmentation and regional forecast.
$2.6B market · 2025 base year
View reportIn Vitro Fertilization (IVF) Equipment Market
Market size, share, segmentation and regional forecast.
$5.9B market · 2025 base year
View reportIn Vitro Fertilization Incubator Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportIn Vitro Fertilization Banking Service Market
Market size, share, segmentation and regional forecast.
$2.6B market · 2025 base year
View reportIn Vitro Diagnostics Test Kit Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportIn Vitro Diagnostic Solution Market
Market size, share, segmentation and regional forecast.
$461M market · 2025 base year
View reportIn–Vitro Diagnostics (IVDs) Medical Device Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportIn-Vitro Diagnostics (IVD) Packaging Market
Market size, share, segmentation and regional forecast.
$6.1B market · 2025 base year
View reportIn-vitro Diagnostics (IVD) Instruments Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportIn Vitro Diagnostics (IVD) Analyzers Market
Market size, share, segmentation and regional forecast.
$992M market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.